A single-centre, placebo-controlled, double-blinded, randomized, crossover study of Iloprost (Ventavis) in patients with Eisenmenger syndrome

Trial Profile

A single-centre, placebo-controlled, double-blinded, randomized, crossover study of Iloprost (Ventavis) in patients with Eisenmenger syndrome

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Jul 2016

At a glance

  • Drugs Iloprost (Primary)
  • Indications Pulmonary hypertension
  • Focus Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 12 Nov 2015 Accrual to date is 106 % as per United Kingdom Clinical Research Network record
    • 11 Nov 2015 Accrual to date is 93% as per United Kingdom Clinical Research Network record.
    • 07 Oct 2015 Accrual to date is 86% as per United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top